Publication | Closed Access

Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes

Cell TherapyTransplantationMarrow TransplantationStem Cell TransplantationHematologyImmunologyImmune RecoveryPre-emptive Rituximab TreatmentImmunotherapyMedicineCell TransplantationGraft RejectionEpstein–barr Virus Reactivation